This trial is testing a new, less invasive way to replace a failing tricuspid valve.
- Tricuspid Regurgitation
1 Primary · 4 Secondary · Reporting Duration: Through 30 days post-procedure
1 Treatment Group
1 of 1
15 Total Participants · 1 Treatment Group
Primary Treatment: Intrepid™ TTVR System · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
To what extent is enrollment in this research endeavor being facilitated?
"To begin the study, 15 eligible participants are necessary. Medtronic Cardiovascular will be managing the experiment from a variety of locations, such as Aurora Saint Luke's Medical in Milwaukee and Abrazo Arizona Heart Hospital in Phoenix." - Anonymous Online Contributor
In which areas can participants access this trial?
"Patients may find enrollment opportunities at 15 different sites, including Aurora Saint Luke's Medical in Milwaukee, Abrazo Arizona Heart Hospital in Phoenix and University of Alabama at Birmingham (UAB) Hospital in Birmingham." - Anonymous Online Contributor
Are there any available openings for participants in this clinical exploration?
"Affirmative. According to the information found on clinicaltrials.gov, this trial was first made available on October 20th 2020 and has been actively recruiting since then; as of November 21st 2022 it is still looking for 15 participants from 15 different locations." - Anonymous Online Contributor